NDA 219474 · Acrotech Biopharma
Adquey
Difamilast · Topical · Phosphodiesterase 4 Inhibitor
NovelCDER novel approval, Feb 12, 2026: To treat mild to moderate atopic dermatitis
Last checked: Nov 19, 2026Latest source record: Feb 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Feb 12, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
14
9 Phase 3, 0 recruiting
FAERS reports
11
9 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 25, 2026.
ADQUEY is indicated for the topical treatment of adults and pediatric patients 2 years of age and older with mild to moderate atopic dermatitis. ADQUEY is a phosphodiesterase 4 inhibitor indicated for the topical treatment of adults and pediatric patients 2 years of age and older with mild to moderate atopic dermatitis. (1)
Mechanism: Difamilast is an inhibitor of phosphodiesterase-4 (PDE-4). Difamilast’s inhibition of PDE-4 (a major cyclic adenosine monophosphate (AMP)-metabolizing enzyme) activity leads to accumulation of intracellular cyclic AMP and decreased productions of various cytokines and chemokines. However, the specific mechanism(s) by which difamilast exerts its therapeutic action is not well defined.
Therapeutic areas: Immunology and inflammation · Dermatology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ADQUEY · DIFAMILAST 1% · OINTMENT, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Difamilast" as an intervention, any sponsor and status, largest first.
- A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic DermatitisPivotal-lookingCompleted
Acrotech Biopharma Inc.Industry
NCT05571943 · 542 participants · Start Sep 15, 2022 · Primary completion Jul 31, 2024
Drug: Difamilast · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Phoenix, Arizona; Jonesboro, Arkansas · 63 sites in all
- Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndromePivotal-lookingCompleted
Otsuka Pharmaceutical Co., Ltd.Otsuka
NCT03908970 · 364 participants · Start Mar 25, 2019 · Primary completion Dec 28, 2019
Drug: 1% OPA-15406; Placebos · For: Atopic Dermatitis
Sites: Sapporo, Japan
- To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With ADPivotal-lookingCompleted
Otsuka Beijing Research InstituteOtsuka
NCT05667623 · 270 participants · Start Feb 6, 2023 · Primary completion Jun 17, 2024
Drug: 1% OPA-15406 Ointment · For: Atopic Dermatitis (AD)
Sites: Beijing, China
- Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic DermatitisPivotal-lookingCompleted
Otsuka Pharmaceutical Co., Ltd.Otsuka
NCT03911401 · 251 participants · Start May 7, 2019 · Primary completion Dec 13, 2019
Drug: 0.3% OPA-15406; 1% OPA-15406 and 1 more · For: Atopic Dermatitis
Sites: Sapporo, Japan
- To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients with ADPivotal-lookingCompleted
Otsuka Beijing Research InstituteOtsuka
NCT05650320 · 240 participants · Start Feb 17, 2023 · Primary completion Jul 21, 2024
Drug: 0.3% OPA-15406 Ointment; 1% OPA-15406 Ointment · For: Atopic Dermatitis (AD)
Sites: Beijing, China
- Study of OPA-15406 Ointment in Patients With Atopic DermatitisPivotal-lookingCompleted
Otsuka Pharmaceutical Co., Ltd.Otsuka
NCT02914548 · 200 participants · Start Sep 2016 · Primary completion Jun 2017
Drug: OPA-15406; Placebo · For: Atopic Dermatitis
Sites: Hokkaido Region, Japan; Kanto Region, Japan; Kiniki Region, Japan
- A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic DermatitisPivotal-lookingNot yet recruiting
Otsuka Pharmaceutical Co., Ltd.Otsuka
NCT07184645 · 198 participants (planned) · Start Sep 2025 · Primary completion Feb 2027
Drug: OPA-15406; Vehicle · For: Atopic Dermatitis (AD)
Sites: Tokyo, Japan
- A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic DermatitisPivotal-lookingNot yet recruiting
Otsuka Pharmaceutical Co., Ltd.Otsuka
NCT07173478 · 156 participants (planned) · Start Oct 2025 · Primary completion Dec 2026
Drug: OPA-15406; Vehicle · For: Atopic Dermatitis (AD)
Sites: Tokyo, Japan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- vomiting2
- blister1
- chills1
- cough1
- cutaneous t-cell lymphoma1
- dermatitis atopic1
- eczema herpeticum1
- eczema nummular1
- erythema1
- erythema multiforme1
- feeding disorder1
- metapneumovirus bronchitis1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 1 |
| 2026 | 10 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
Chu DK, Chu AWL, Rayner DG, et al. · J Allergy Clin Immunol 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Topical anti-inflammatory treatments for eczema: network meta-analysis.
Lax SJ, Van Vogt E, Candy B, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Difamilast ointment in adult patients with atopic dermatitis: A phase 3 randomized, double-blind, vehicle-controlled trial.
Saeki H, Ito K, Yokota D, et al. · J Am Acad Dermatol 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Clinical efficacy and safety of topical difamilast in the treatment of patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials.
Lu LC, Chao CM, Chang SP, et al. · Expert Rev Clin Pharmacol 2022 · Meta-Analysis, Systematic Review
- New molecules for atopic dermatitis treatment beyond biological therapy.
Freitas E, Torres T · Curr Opin Allergy Clin Immunol 2023 · Review, Meta-Analysis
- Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial.
Saeki H, Baba N, Ito K, et al. · Br J Dermatol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Acrotech Biopharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.